[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594444":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":79,"collaborators":81,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":35,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":64,"whyStopped":35,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Saline","ACTIVE_COMPARATOR","Saline infusion, oral glucose (POTS and healthy)",[13],"Other: Saline\u002FPlacebo",{"label":15,"type":16,"description":17,"interventionNames":18},"GIP antagonist","EXPERIMENTAL","GIP(3-30)NH2 infusion, oral glucose (POTS and healthy)",[19],"Other: GIPR antagonist",{"label":21,"type":16,"description":22,"interventionNames":23},"GLP-1 antagonist","Exendin(9-39)NH2 infusion, oral glucose (only in healthy)",[24],"Other: GLP-1R antagonist",{"label":26,"type":16,"description":27,"interventionNames":28},"CCK agonist","CCK-8 infusion, oral glucose (POTS and healthy)",[29],"Other: CCK agonist",[31,36,40,44],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Saline\u002FPlacebo","NaCl(9mg\u002Fml)",[9],null,{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"GIPR antagonist","GIP(3-30)NH2",[15],{"type":6,"name":41,"description":42,"armGroupLabels":43,"otherNames":35},"GLP-1R antagonist","GLP-1(9-39)NH2",[21],{"type":6,"name":26,"description":45,"armGroupLabels":46,"otherNames":35},"CCK-8",[26],[48],{"name":49,"affiliation":50,"role":51},"Lærke S Gasbjerg, MD, PhD","University of Copenhagen, Rigshospitalet","STUDY_CHAIR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":35,"email":57},"Sophie W Nielsen, MD","CONTACT","+ 45 27 26 79 94","sophie.nielsen@sund.ku.dk",{"name":49,"role":55,"phone":59,"phoneExt":35,"email":60},"+45 25 34 68 94","lsg@sund.ku.dk",[62],{"facility":63,"status":64,"city":65,"state":35,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Rigshospitalet","RECRUITING","Copenhagen","2100","Denmark","DK",{"type":70,"coordinates":71},"Point",[72,73],12.56553,55.67594,{"lat":73,"lon":72},[76],{"name":54,"role":55,"phone":77,"phoneExt":78,"email":57},"27 26 79 94","+45",{"type":80,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[82],{"name":83,"class":6},"Rigshospitalet, Denmark","100594444","pots-flow-interplay-between-gut-hormones-and-autonomic-postprandial-blood-flow-regulation-in-patients-with-pots-100594444",false,"NCT07019519","POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS","Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS","GA22","Inclusion Criteria POTS patients:\n\n* Previously diagnosed with POTS in tilt test or active stand-test (either newly diagnosed within last 3 months or in new tilt test\u002Factive stand test during screenings visit)\n* Reproducible orthostatic intolerance with raise in HR on \\>30 bpm when standing within 10 minutes of change of supine to standing in age \\>19 years or \\>40 bpm in age 18-19 years.\n* POTS symptoms\u002Forthostatic intolerance\n* Age 18-50\n* Waist ratio \\\u003C180 cm\n\nExclusion Criteria:\n\n* Chronic illness\n* Metallic implants\n* Above 10 alcoholic drinks or week or substance abuse\n* Other types of sinus tachycardia or heart disease\n* Liverenzymes two times above normal values\n* Decreased kidney function eGFR \\\u003C90 or elevated kreatinkinasis\n* Thyroid disease or TSH out of reference\n* Uncontrollable low or high blood pressure\n* Blood vessels that cannot be visualized on MR\n* Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours\n\nInclusion Criteria:\n\n* Age 18-50\n* Waist ratio \\\u003C180 cm\n* Matched a POTS patient in age, sex and BMI\n\nExclusion Criteria:\n\n* Chronic illness\n* Metallic implants\n* Above 10 alcoholic drinks or week or substance abuse\n* POTS; other types of sinus tachycardia or heart disease\n* Liverenzymes two times above normal values\n* Decreased kidney function eGFR \\\u003C90 or elevated kreatinkinasis\n* Thyroid disease or TSH out of reference\n* Uncontrollable low or high blood pressure, Orthostatic hypotension\n* Blood vessels that cannot be visualized on MR\n* Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours",true,"ALL","18 Years","50 Years",{"count":97,"type":98},30,"ESTIMATED","INTERVENTIONAL",[101],"NA","This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.",[104,105],"Postural Orthostatic Tachycardia Syndrome (POTS)","Healthy",[107,108,109,110,111,112,113,114,45,115,116],"Postural Orthostatic Tachycardia Syndrome","POTS","Glucose-dependent insulinotropic polypeptide","GIP","Glucagon-like peptide-1","Glucagon-like peptide-2","GLP-1","GLP-2","Cholecystokinin","Splanchnic Blood Flow","2025-06-10",{"date":119,"type":120},"2025-06-13","ACTUAL",{"date":122,"type":120},"2025-03-15",{"date":124,"type":98},"2026-09-30",{"name":5,"class":6},1]